why choose us

Clinical Trials Search

Showing 8,770 of 132,656 result(s)
Study of 3D Scanning for Adolescent Scoliosis

Status: Completed

Condition: Scoliosis

Interventions: Subjects will undergo a quick, radiation-free, no contact 3D scan using a smartphone.

Date: 2023-08-31

Early Total Enteral Feeding Versus Convention Enteral Feeding in Preterm Infants 27-32 Weeks of Gestation

Status: Completed

Condition: Very Preterm Maturity of Infant

Interventions: This group will receive enteral feeding volumes at a rate of 80 ml;kg;day starting within the first two hours after birth.
Volumes will

Date: 2023-08-31

Thromboembolic Risk Assessment in Patients Admitted With Acute Medical Diseases to Conventional and At Home Hospitalization

Status: Completed

Condition: Thromboprophylaxis

Interventions: A group of patients will be controlled with triaxial accelerometer (GENEActiv watch) on left wrist at a sampling rate of 85,70 Hz to measure movement

Date: 2023-08-31

Assessment of Hypoxia Before Radioembolization Treatment With 18F-FMISO PET

Status: COMPLETED

Condition: Radioembolization

Interventions: Imaging of hypoxia before radioembolization with 18F-Fluoromisonidazole PET.

Date: 2023-08-31

Depression Return to Work Intervention

Status: COMPLETED

Condition: Job Stress

Interventions: Participants will complete the six-week DRIVEN program, which includes a smartphone application and job coaching.

Date: 2023-08-30

A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

Status: ACTIVE_NOT_RECRUITING

Condition: Solid Tumor, Adult

Interventions: Intra-tumoral administration on Days 1 and 15 of every 28-day cycle

Date: 2023-08-30

A Sequential Single and Multiple Ascending Dose (SAD;MAD) Study of SK10 Powders in Healthy Adult Subjects

Status: Completed

Condition: Chemotherapy-induced Diarrhea

Interventions: Participants will be randomized to receive oral suspension of SK10 powder, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.

Date: 2023-08-30

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Status: NOT_YET_RECRUITING

Condition: Fibrolamellar Hepatocellular Carcinoma

Interventions: Patients will receive treatment on Day 1 of each cycle.
Durvalumab (1500 mg) will be administered IV on Day 1 of each cycle every 28 days.

Date: 2023-08-30

Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants

Status: NOT_YET_RECRUITING

Condition: Premature Birth

Interventions: The novel smallTalk NICU Active product design allows a disposable pacifier (equipped with the smallTalk sensor) to act as an infant-controlled mechan

Date: 2023-08-30